← Back to Clinical Trials
Recruiting NCT06730334

NCT06730334 Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06730334
Status Recruiting
Phase
Sponsor Nanjing Medical University
Condition Psoriatic Arthritis
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2023-09-01
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2023-09-01 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and clinical domains including skins and nails as well as arthritis, spondylitis, enthesitis, and dactylitis. Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess disease activity and treatment response in PsA. This is a prospective, observational, open-label study to investigate disease activity, therapeutic response and bone destruction based on ultrasonography findings in patients with PsA.

Eligibility Criteria

Inclusion Criteria: * PsA patients as defined by CASPAR criteria * Patients must be able to comply with the visit schedule, treatment plan, laboratory tests and other study procedures * Patients must be given informed consent Exclusion Criteria: * History of other arthritis within the last 12 months * Concomitant disease with acute or chronic infectious diseases * Pregnancy or laction * Poorly tolerated with venipuncture required for blood sampling during the study

Contact & Investigator

Central Contact

Rui Rui LIU, MD

✉ liurui_nanjing@163.com

📞 +86 15951871668

Frequently Asked Questions

Who can join the NCT06730334 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriatic Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06730334 currently recruiting?

Yes, NCT06730334 is actively recruiting participants. Contact the research team at liurui_nanjing@163.com for enrollment information.

Where is the NCT06730334 trial being conducted?

This trial is being conducted at Nanjing, China, Nanjing, China.

Who is sponsoring the NCT06730334 clinical trial?

NCT06730334 is sponsored by Nanjing Medical University. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology